New study seeks safer dosing of cancer drug for patients with liver issues
NCT ID NCT07036133
First seen Feb 17, 2026 · Last updated Jun 23, 2026 · Updated 20 times
Summary
This early-stage study tests the drug pralatrexate in 24 adults with advanced cancer and varying levels of liver function. The goal is to see how the body processes the drug and to find the right dose for people with mild, moderate, or severe liver impairment. Participants receive the drug weekly for six weeks, followed by a week off, while researchers monitor side effects and drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gabrail Cancer Center
RECRUITINGCanton, Ohio, 44718, United States
Contact
-
Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
Contact
-
Northwestern University - Feinberg School of Medicine
RECRUITINGChicago, Illinois, 60611, United States
Contact
-
TOI Clinical Research
WITHDRAWNCerritos, California, 90703, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pralatrexate
What this could lead to
If successful, this study could help doctors safely dose pralatrexate in cancer patients with liver problems, expanding treatment options.
What could go wrong
This is a very early, small Phase 1 trial focused on safety and dosing, not on curing cancer. The drug may not work well or could cause side effects, especially in those with severe liver impairment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.